Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
CURRENT ASSETS:
Cash and cash equivalents	$ 20,958	$ 11,092
Accounts receivable, net of allowance for credit losses of $3,313 and $2,730 at 2020 and 2019, respectively	101,464	131,579
Inventories	41,528	50,163
Prepaid expenses	12,617	15,951
Income taxes receivable	8,534	6,527
Other current assets	6,292	5,925
TOTAL CURRENT ASSETS	191,393	221,237
PROPERTY, PLANT AND EQUIPMENT, net	119,866	123,506
RIGHT OF USE ASSETS	70,147	75,697
INTANGIBLES, net	8,743	17,450
GOODWILL	99,445	213,425
DEFERRED TAX ASSETS, net	71,805	67,312
OTHER ASSETS	53,042	56,046
TOTAL ASSETS	614,441	774,673
CURRENT LIABILITIES:
Accounts payable	23,693	35,611
Accrued payroll and related costs	34,663	26,689
Taxes other than payroll and income	5,633	8,366
Unearned revenues	10,513	13,381
Operating lease liabilities	12,028	11,841
Income taxes payable	3,306	6,324
Other current liabilities	9,448	9,382
TOTAL CURRENT LIABILITIES	99,284	111,594
LONG-TERM DEBT, net	286,610	305,283
LONG-TERM OPERATING LEASE LIABILITIES	57,449	64,660
DEFERRED COMPENSATION	49,267	50,485
DEFERRED TAX LIABILITIES, net	24,277	27,338
OTHER LONG-TERM LIABILITIES	31,407	33,173
COMMITMENTS AND CONTINGENCIES
EQUITY:
Preference shares, EUR 0.02 par value; 6,000,000 shares authorized, none issued or outstanding	0	0
Common shares, EUR 0.02 par value; 200,000,000 shares authorized, 44,796,252 issued and 44,477,267 outstanding at 2020 and 44,796,252 issued and 44,465,562 outstanding at 2019	1,148	1,148
Additional paid-in capital	60,901	51,872
Retained earnings	34,846	160,539
Accumulated other comprehensive income (loss)	(8,358)	(6,330)
Treasury shares (at cost), 318,985 at 2020 and 330,690 at 2019	(26,434)	(29,364)
Total Core Laboratories N.V. shareholders' equity	62,103	177,865
Non-controlling interest	4,044	4,275
TOTAL EQUITY	66,147	182,140
TOTAL LIABILITIES AND EQUITY	$ 614,441	$ 774,673